tumor sequencing
The genetic testing and health intelligence firm will start trading on the Nasdaq Global Select Market on Friday under the ticker symbols SMFR and SMFRW.
Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year
Premium
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.
With its liquid biopsy test FDA approved and monitoring and screening offerings poised for launch, the firm is turning its attention to tumor tissue testing.
Germline Genetic Testing After Tumor Sequencing Can Uncover Clinically Actionable Variants
An Invitae-led retrospective study found almost a third of cancer patients who underwent germline genetic testing after tumor sequencing had pathogenic variants.
Patient Education Project Identifies Need for Consistent Terms in Cancer Testing
The LUNGevity Foundation and 41 stakeholders aim to reduce cancer patients' confusion about in vitro diagnostic testing by implementing two consistent umbrella terms.